Estimating the indirect costs associated with psoriasis
- 3 October 2022
- journal article
- research article
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 103 (5) , 824-831
Abstract
Background. The assessment of indirect economic costs associated with psoriasis is relevant due to the poor knowledge of the impact of the disease on key performance indicators, as well as the question of how the expansion of the pool of patients receiving genetically engineered biological drugs affects the indirect costs associated with the disease. Aim. Evaluation of the indirect economic burden of psoriasis associated with missed work time and reduced performance in the actual presence at the workplace, as well as an assessment of the impact of changing the structure of therapy on indirect costs. Material and methods. To calculate the indirect economic burden of psoriasis using the human capital method, two approaches were used: through an assessment of the impact on gross domestic product and through the use of the market value of working hours. A Bayesian network meta-analysis was performed to assess the impact of genetically engineered biologics on the indirect economic costs associated with psoriasis. Systematic search and selection of studies for network meta-analysis was performed using several databases (clinicaltrials.gov, Eu Clinical Trials, Pubmed, WHO ICTRP, medRxiv). Studies in patients with moderate to severe psoriasis treated with any genetically engineered biological drug were included. Results. Indirect economic losses calculated through the assessment of the impact on the gross domestic product amounted to 10.2 billion rubles per year, and through the application of the market value of working time 17.9 billion rubles per year per 100,000 patients with psoriasis in 2018 in Russian Federation. The genetically engineered biological drugs prescription can lead to a reduction in the annual indirect economic burden by 4.9 billion rubles and 8.6 billion rubles per 100,000 economically active patients with moderate and severe psoriasis, calculated through the assessment of the impact on the gross domestic product and through the application of the market value of working hours, respectively. Conclusion. A decrease in the work productivity of patients with psoriasis leads to significant indirect costs, while an increase in the proportion of patients receiving genetically engineered biological drugs leads to a decrease in the indirect economic burden on the state and society as a whole.Keywords
This publication has 17 references indexed in Scilit:
- Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003–2011PLOS ONE, 2012
- Socioeconomic Burden of Immune-Mediated Inflammatory Diseases -- Focusing on Work Productivity and DisabilityThe Journal of Rheumatology, 2011
- The value of productivity: human-capital versus friction-cost methodAnnals of the Rheumatic Diseases, 2010
- The Cost and Impact of Health Conditions on Presenteeism to EmployersPharmacoEconomics, 2009
- The impact of psoriasis on health care costs and patient work lossJournal of the American Academy of Dermatology, 2008
- Work Limitations and Productivity Loss Are Associated with Health-Related Quality of Life but Not with Clinical Severity in Patients with PsoriasisDermatology, 2006
- Cost‐of‐illness in patients with moderate and severe chronic psoriasis vulgaris in GermanyJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2005
- Production gains from health care: what should be included in cost-effectiveness analyses?Social Science & Medicine, 1999
- The friction cost method for measuring indirect costs of diseaseJournal of Health Economics, 1995
- Cost-effectiveness analysis: is it ethical?Journal of Medical Ethics, 1992